Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glo-BNHL: Novel Agents in Paediatric and Adolescent Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT05991388Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- May 2024
- Primary completion
- May 2031
- Modality
- Gene Editing, Gene Silencing, Bispecific Antibodies
- Countries
- 7
01
Overview
Phase 3, open-label trial of odronextamab, loncastuximab tesirine and CAR T-cells (Glo-BNHL) in B-cell non-Hodgkin lymphoma (3 arms), sponsored by University of Birmingham. Primary endpoints: Objective Response at cycle 3 and Complete Response at cycle 3. Started May 2024; status: recruiting.
02
Drugs
odronextamabloncastuximab tesirineCAR T-cells (Glo-BNHL)
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05991388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05991388.